Table 1 Pan-urologic cancer genomic subtypes
From: Pan-urologic cancer genomic subtypes that transcend tissue of origin
Subtype (n cases) | Associated cancer types (%) | Associated external subtypes | Survival association | Associated pathways |
|---|---|---|---|---|
c1 (216) | BLCA (56), KICH (23), KIRP (19) | BLCA:c1 luminal, BLCA:papillary histology, KIRP:type 1 histology | BLCA:better, KIRP:worse | fatty acid synthesis |
c2 (333) | BLCA (28), PRAD (59), KIRP (6), KIRC (5) | PRAD:ERG fusion, PRAD:iCluster2, PRAD:meth. cluster3, BLCA:c2 lum. immune | BLCA:worse, PRAD:worse | PTEN loss (PRAD), Hippo |
c3 (106) | KIRP (72), KIRC (10), PRAD (8), KICH (6) | KIRP:type 1 histology, RCC:P-e.1b | intermediate | |
c4 (253) | PRAD (70), TGCT (28) | PRAD:ETV fusion/high, PRAD:iCluster1, PRAD:meth. cluster2, TGCT:seminoma | PRAD:worse | SPOP and FOXA1 mutations (PRAD), KIT and KRAS mutations (TGCT), Hippo, immune checkpoint |
c5 (269) | KIRC (62), KIRP (38) | RCC:CC-e.3, RCC:P-e.2, RCC:P.CIMP-e, RCC:hypermeth., KIRP:type 2 histology | KIRC:worse, KIRP:worse | fatty acid synthesis, pentose phosphate, Hypoxia, EMT, NRF2-ARE, Hippo, immune checkpoint |
c6 (268) | KIRC (52), KIRP (18), TGCT (30) | RCC:CC-e.2, RCC:mixed, TGCT:non-seminoma | KIRC:better, KIRP:better | |
c7 (202) | KIRC (98) | RCC:CC-e.1, RCC:CC-e.2 | intermediate | |
c8 (192) | BLCA (99) | PanCan12:squamous, BLCA:c2 lum. immune BLCA:c3 basal BLCA:c4 immune undiff. | worse | Hypoxia, EMT, NRF2-ARE, immune checkpoint |
c9 (115) | PRAD (100) | PRAD:ERG fusion, PRAD:iCluster3, PRAD:meth. cluster4 | better | Hypoxia, EMT, NRF2-ARE, immune checkpoint |
